Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: A retrospective study

Virology Journal

Volumn 9, Issue , 2012, Pages

  Nagao, Yumiko ^a   Kawaguchi, Takumi ^a   Ide, Tatsuya ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Branched chain amino acids (BCAA); Hepatitis C virus (HCV); Interferon (IFN); Low dose long term IFN therapy; Standard IFN therapy

Indexed keywords

AMINO ACID; AMINOFEEL; BETA INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DIET SUPPLEMENTATION; FEMALE; HEPATITIS C; HUMAN; JAPANESE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; AMINO ACIDS, BRANCHED-CHAIN; ANTIVIRAL AGENTS; DIETARY SUPPLEMENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84869861218     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-282     Document Type: Article

References (36)

1. Hepatocellular carcinoma: recent trends in Japan. Kiyosawa K, Uemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E, Gastroenterology 2004 127 Suppl 1 17 26 15236168
2. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N, Hepatology 2010 52 518 527 10.1002/hep.23691 20683951
3. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M, Ann Intern Med 1999 131 174 181 10428733 (Pubitemid 29364999)
4. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M, Gastroenterology 2002 123 483 491 10.1053/gast.2002.34785 12145802 (Pubitemid 34827193)
5. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT-C Trial Group, Gastroenterology 2011 140 840 849 10.1053/j.gastro.2010.11.050 21129375
6. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
7. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J, N Engl J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
8. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group, Ann Intern Med 2004 140 346 355 14996676
9. Side effects of therapy of hepatitis C and their management. Fried MW, Hepatology 2002 36 Suppl 1 237 244
10. Side effects of therapy for chronic hepatitis C. Russo MW, Fried MW, Gastroenterology 2003 124 1711 1719 10.1016/S0016-5085(03)00394-9 12761728 (Pubitemid 36617688)
11. Effects of oral branchedchain amino acid granules on event-free survival in patients with liver cirrhosis. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Long-Term Survival Study Group, Clin Gastroenterol Hepatol 2005 3 705 713 10.1016/S1542-3565(05)00017-0 16206505 (Pubitemid 40984733)
12. Anticatabolic effect of branched-chain amino acid-enriched solutions in patients with liver cirrhosis. Marchesini G, Zoli M, Dondi C, Bianchi G, Cirulli M, Pisi E, Hepatology 1982 2 420 425 7095743 (Pubitemid 12046836)
13. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. Honda M, Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S, Hokuriku Liver Study Group, Gastroenterology 2011 141 128 140 10.1053/j.gastro.2011.03.051 21458454
14. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M, Int J Mol Med 2008 22 105 112 18575782
15. Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases. Kawaguchi T, Taniguchi E, Itou M, Sumie S, Oriishi T, Matsuoka H, Nagao Y, Sata M, Liver Int 2007 27 1287 1292 17919242 (Pubitemid 47543159)
16. Aminofeel® improves the sensitivity to taste in patients with HCV-infected liver disease. Nagao Y, Matsuoka H, Kawaguchi T, Sata M, Med Sci Monit 2010 16 7 12
17. Post-marketing surveillance study for efficacy and safety of Aminofeel®, a branched chain amino acid-enriched supplement including zinc. Nagao Y, Kawaguchi T, Kakuma T, Ide T, Sata M, J New Rem & Clin 2011 60 1046 1063 in Japanese 23174692
18. Ammonia metabolism, the brain and fatigue; revisiting the link. Wilkinson DJ, Smeeton NJ, Watt PW, Prog Neurobiol 2010 91 200 219 10.1016/j.pneurobio. 2010.01.012 20138956
19. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG, Br J Cancer 2002 86 1691 1696 10.1038/sj.bjc. 6600336 12087451 (Pubitemid 34712909)
20. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. Yamamoto M, Iwasa M, Matsumura K, Nakagawa Y, Fujita N, Kobayashi Y, Kaito M, Takeda K, Adachi Y, World J Gastroenterol 2005 11 6792 6799 16425386 (Pubitemid 43092450)
21. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Kawaguchi T, Izumi N, Charlton MR, Sata M, Hepatology 2011 54 1063 1070 21563202
22. Decreased regional cerebral blood flow during interferon therapy. Sasaki M, Sara M, Ishibashi M, Uchimura N, Tanikawa K, Hepatol Res 1997 9 1 8 10.1016/S1386-6346(97)00072-7 (Pubitemid 28023383)
23. Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Nagao Y, Sata M, Virol J 2010 7 375 10.1186/1743-422X-7-375 21194423
24. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M, Hepatology 1994 20 558 564 10.1002/hep.1840200303 7521313 (Pubitemid 24271261)
25. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H, Cancer 1997 79 1494 1500 10.1002/(SICI)1097- 0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B 9118029 (Pubitemid 27154778)
26. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW, J Gastroenterol Hepatol 1999 14 1093 1099 10.1046/j.1440-1746.1999.02008.x 10574137
27. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro T, Sata M, Dig Dis Sci 2006 51 808 812 10.1007/s10620-006-3211-2 16615008
28. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, Ishibashi H, Hepatol Res 2007 37 490 497 10.1111/j.1872-034X.2007.00073.x 17539990 (Pubitemid 46864243)
29. Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report. Kawaguchi T, Sumie S, Itou M, Taniguchi E, Matoba T, Sata M, Dig Dis Sci 2009 54 690 694 10.1007/s10620-008-0397-5 18661237
30. A case of chronic hepatitis C with sustained virological response by an intermittent use of low dose pegylated interferon. Shima C, Yamada A, Tsubosaka M, Sakurai M, Nakatani K, Kinoshita K, Kishida O, Fujimoto T, Minami Y, Kanzo 2008 49 470 475 in Japanese 10.2957/kanzo.49.470
31. Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. Nagao Y, Sata M, J Gastroenterol Hepatol 2008 23 580 585 10.1111/j.1440-1746.2007.04835.x 18397487 (Pubitemid 351501137)
32. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M, J Clin Microbiol 2000 38 4171 4179 11060086 (Pubitemid 32233222)
33. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus S, Zadak M, Babiel R, J Clin Virol 2007 38 326 333 10.1016/j.jcv.2006.12.021 17344093 (Pubitemid 46414003)
34. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P, Hepatology 1994 19 13 18 10.1002/hep.1840190104 8276349 (Pubitemid 24020465)
35. Blood glucose monitors and data management. Guide ADAR, Diabetes Forecast 2003 2003 56 77 79
36. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 157 2413 2446 9385294